<unk> , sold under the brand name Rydapt & Tauritmo both by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Midostaurin
Selepressin
Celadrin 
Angiozyme
Asfotase alfa
Velmanase alfa
Enasidenib
Darobactin